Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern
2020 · External reference
10.1056/nejmoa2015301
10.1056/nejmoa2015301 · External reference
10.1038/s41422-020-00450-0
10.1038/s41422-020-00450-0 · External reference
10.1038/s41586-021-03431-4
10.1038/s41586-021-03431-4 · External reference
10.1038/s41586-020-2901-9
10.1038/s41586-020-2901-9 · External reference
10.1126/science.abf4058
10.1126/science.abf4058 · External reference
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
10.1016/j.phrs.2020.104761 · 2020 · External reference
Protection against COVID-19 injury by Qingfei Paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming
10.1016/j.biopha.2020.110281 · 2020 · External reference
10.1056/nejmoa2023184
10.1056/nejmoa2023184 · External reference
A living WHO guideline on drugs to prevent covid-19
10.1136/bmj.n526 · 2021 · External reference
Many small steps towards a COVID-19 drug
10.1038/s41467-020-18710-3 · 2020 · External reference
10.1016/j.apsb.2020.04.009
10.1016/j.apsb.2020.04.009 · External reference
Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro
10.1038/s41392-020-0178-y · 2020 · External reference
10.1007/s10930-020-09933-w
10.1007/s10930-020-09933-w · External reference
10.1038/s41589-020-00689-z
10.1038/s41589-020-00689-z · External reference
10.1021/acs.jpclett.0c00994
10.1021/acs.jpclett.0c00994 · External reference
10.1038/s41467-020-18233-x
10.1038/s41467-020-18233-x · External reference
10.1038/s41467-021-21060-3
10.1038/s41467-021-21060-3 · External reference
10.1126/science.abb3405
10.1126/science.abb3405 · External reference
10.1021/acs.jpclett.0c01828
10.1021/acs.jpclett.0c01828 · External reference
10.1016/j.celrep.2020.107774
10.1016/j.celrep.2020.107774 · External reference
10.1021/acscentsci.0c01242
10.1021/acscentsci.0c01242 · External reference
10.1038/s41586-020-2368-8
10.1038/s41586-020-2368-8 · External reference
10.1038/s41586-021-03402-9
10.1038/s41586-021-03402-9 · External reference
10.15252/embj.2020106275
10.15252/embj.2020106275 · External reference
10.1126/sciadv.abd4596
10.1126/sciadv.abd4596 · External reference
10.1126/scitranslmed.abc5332
10.1126/scitranslmed.abc5332 · External reference
10.1093/bib/bbaa382
10.1093/bib/bbaa382 · External reference
10.1038/s41467-020-16954-7
10.1038/s41467-020-16954-7 · External reference
10.1126/science.abb7498
10.1126/science.abb7498 · External reference
10.1038/s41586-020-2180-5
10.1038/s41586-020-2180-5 · External reference
10.1016/j.cell.2020.03.045
10.1016/j.cell.2020.03.045 · External reference
10.1021/acs.jmedchem.0c00606
10.1021/acs.jmedchem.0c00606 · External reference
10.1002/med.21763
10.1002/med.21763 · External reference
10.1002/med.21776
10.1002/med.21776 · External reference
Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: State of the art and future opportunities
2021 · External reference
10.1016/j.drudis.2020.12.005
10.1016/j.drudis.2020.12.005 · External reference
10.1016/j.ejmech.2021.113201
10.1016/j.ejmech.2021.113201 · External reference
10.1016/j.ejmech.2020.112711
10.1016/j.ejmech.2020.112711 · External reference
COVID-19: Inflammatory responses, structure-based drug design and potential therapeutics
2021 · External reference
10.1002/med.21783
10.1002/med.21783 · External reference
10.3390/molecules25235695
10.3390/molecules25235695 · External reference
10.1016/j.csbj.2021.05.043 · Admitted local publication
10.1016/j.csbj.2020.11.010 · Admitted local publication
10.1016/j.csbj.2021.04.059 · Admitted local publication
10.1016/j.ejphar.2021.174082
10.1016/j.ejphar.2021.174082 · External reference
Exploring phytochemicals of traditional medicinal plants exhibiting inhibitory activity against main protease, Spike glycoprotein, RNA-dependent RNA polymerase and non-structural proteins of SARS-CoV-2 through virtual screening
10.3389/fphar.2021.667704 · 2021 · External reference
10.1002/med.21474
10.1002/med.21474 · External reference
The strategies and techniques of drug discovery from natural products
10.1016/j.pharmthera.2020.107686 · 2020 · External reference
10.1038/s41573-020-00114-z
10.1038/s41573-020-00114-z · External reference
10.1038/nrd4510
10.1038/nrd4510 · External reference
Turning the tide: Natural products and natural-product-inspired chemicals as potential counters to SARS-CoV-2 infection
10.3389/fphar.2020.01013 · 2020 · External reference
10.1021/acs.jnatprod.0c00968
10.1021/acs.jnatprod.0c00968 · External reference
10.3390/biomedicines9060689
10.3390/biomedicines9060689 · External reference
Current prevention of COVID-19: Natural products and herbal medicine
10.3389/fphar.2020.588508 · 2020 · External reference
10.1016/j.jep.2021.113869
10.1016/j.jep.2021.113869 · External reference
10.1016/j.phymed.2020.153311
10.1016/j.phymed.2020.153311 · External reference
An untargeted metabolomics approach to investigate the wine-processed mechanism of Scutellariae radix in acute lung injury
10.1016/j.jep.2020.112665 · 2020 · External reference
Differences in anti-inflammatory effects between two specifications of Scutellariae Radix in LPS-induced macrophages in vitro
10.1016/s1875-5364(17)30077-8 · 2017 · External reference
10.1080/14756366.2021.1873977
10.1080/14756366.2021.1873977 · External reference
10.1038/s41401-020-0496-1
10.1038/s41401-020-0496-1 · External reference
10.1016/j.chemosphere.2020.127038
10.1016/j.chemosphere.2020.127038 · External reference
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
10.1016/j.bcp.2020.114302 · 2021 · External reference
10.1038/s41401-020-0483-6
10.1038/s41401-020-0483-6 · External reference
Myricetin ameliorates sepsis-associated acute lung injury in a murine sepsis model
10.1007/s00210-020-01880-8 · 2021 · External reference
10.1016/j.biopha.2020.111017
10.1016/j.biopha.2020.111017 · External reference
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
10.1038/s41467-021-23751-3 · 2021 · External reference
10.1021/acsptsci.0c00216
10.1021/acsptsci.0c00216 · External reference
10.1016/j.foodchem.2020.128933
10.1016/j.foodchem.2020.128933 · External reference
Phytochemical constituents, distributions and traditional usages of Arnebia euchroma: A review
10.1016/j.jep.2021.113896 · 2021 · External reference
10.1128/aac.47.9.2810-2816.2003
10.1128/aac.47.9.2810-2816.2003 · External reference
10.1038/s41586-020-2223-y
10.1038/s41586-020-2223-y · External reference
Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode
10.1016/j.scib.2020.10.018 · 2021 · External reference
10.1126/science.abb4489
10.1126/science.abb4489 · External reference
10.1021/acsptsci.0c00130
10.1021/acsptsci.0c00130 · External reference
A comprehensive analysis of cis-acting RNA elements in the SARS-CoV-2 genome by a bioinformatics approach
10.3389/fgene.2020.572702 · 2020 · External reference
10.1038/s41467-020-17496-8
10.1038/s41467-020-17496-8 · External reference
Genomewide analysis of mode of action of the s-adenosylmethionine analogue sinefungin in leishmania infantum
10.1128/msystems.00416-19 · 2019 · External reference
10.1016/j.csbj.2020.09.032 · Admitted local publication
In silico identification of novel SARS-COV-2 2′-O-methyltransferase (nsp16) inhibitors: Structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches
10.1080/14756366.2021.1885396 · 2021 · External reference
10.1038/s41467-020-17495-9
10.1038/s41467-020-17495-9 · External reference
10.1016/j.mam.2021.100943
10.1016/j.mam.2021.100943 · External reference
10.1126/science.abd3255
10.1126/science.abd3255 · External reference
The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour
2021 · External reference
Development of hippocampal long-term potentiation is reduced by recently introduced calpain inhibitors
10.1016/0006-8993(90)90660-4 · 1990 · External reference
10.1021/acsinfecdis.0c00761
10.1021/acsinfecdis.0c00761 · External reference
10.1038/s41422-020-0356-z
10.1038/s41422-020-0356-z · External reference
10.1126/sciadv.abe0751
10.1126/sciadv.abe0751 · External reference
Remdesivir metabolite GS-441524 effectively inhibits SARS-CoV-2 infection in mouse models
2021 · External reference
10.1038/s41467-020-20542-0
10.1038/s41467-020-20542-0 · External reference
10.1039/d0nj02656e
10.1039/d0nj02656e · External reference
Remdesivir against COVID-19 and other viral diseases
2021 · External reference
Practical synthesis of 1′-substituted tubercidin C-nucleoside analogs
10.1016/j.tetlet.2011.11.055 · 2012 · External reference
10.1038/nature17180
10.1038/nature17180 · External reference
10.1021/acs.jmedchem.6b01594
10.1021/acs.jmedchem.6b01594 · External reference
10.1039/d0cp05948j
10.1039/d0cp05948j · External reference
10.1002/anie.202011527
10.1002/anie.202011527 · External reference
10.1021/acsmedchemlett.0c00316
10.1021/acsmedchemlett.0c00316 · External reference
10.1021/acs.jpcb.0c06747
10.1021/acs.jpcb.0c06747 · External reference
10.1126/science.abc1560
10.1126/science.abc1560 · External reference
Elucidation of cryptic and allosteric pockets within the SARS-CoV-2 main protease
2021 · External reference
10.1038/s41557-021-00707-0
10.1038/s41557-021-00707-0 · External reference
10.1101/2021.05.05.442536
10.1101/2021.05.05.442536 · External reference
Molecular dynamics simulations reveal the interaction fingerprint of remdesivir triphosphate pivotal in allosteric regulation of SARS-CoV-2 RdRp
10.3389/fmolb.2021.639614 · 2021 · External reference
Remdesivir strongly binds to RNA-dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: Indication from molecular modelling and simulations
10.3389/fphar.2021.710778 · 2021 · External reference
10.1126/scitranslmed.aal3653
10.1126/scitranslmed.aal3653 · External reference
10.1038/s41467-019-13940-6
10.1038/s41467-019-13940-6 · External reference
10.1016/j.antiviral.2019.104541
10.1016/j.antiviral.2019.104541 · External reference
10.1038/s41598-018-22328-3
10.1038/s41598-018-22328-3 · External reference
10.1016/s1473-3099(19)30291-9
10.1016/s1473-3099(19)30291-9 · External reference
10.1073/pnas.1922083117
10.1073/pnas.1922083117 · External reference
10.1016/s0140-6736(16)30386-5
10.1016/s0140-6736(16)30386-5 · External reference
Remdesivir: A pendulum in a pandemic
10.1136/bmj.m4560 · 2020 · External reference
10.1056/nejmoa2031994
10.1056/nejmoa2031994 · External reference
10.1101/2020.11.19.20234153
10.1101/2020.11.19.20234153 · External reference
10.1016/j.csbj.2020.11.056
10.1016/j.csbj.2020.11.056 · External reference
Repurposing anticancer drugs for the management of COVID-19
10.1016/j.ejca.2020.09.014 · 2020 · External reference
Drug repurposing: New strategies for addressing COVID-19 outbreak
10.1080/14787210.2021.1851195 · 2021 · External reference
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
10.1016/j.phrs.2020.104960 · 2020 · External reference
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
10.1016/j.pharmthera.2020.107512 · 2020 · External reference
Favipiravir and the need for early ambulatory treatment of SARS-CoV-2 infection (COVID-19)
10.1128/aac.02017-20 · 2020 · External reference
10.1038/s41422-020-0282-0
10.1038/s41422-020-0282-0 · External reference
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
10.1038/s41467-021-21992-w · 2021 · External reference
The combined treatment of molnupiravir and favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
2021 · External reference
10.1016/j.ijid.2020.11.142
10.1016/j.ijid.2020.11.142 · External reference
10.1128/aac.01897-20
10.1128/aac.01897-20 · External reference
Favipiravir versus arbidol for COVID-19: A randomized clinical trial
2020 · External reference
Experimental treatment with favipiravir for COVID-19: An open-label control study
10.1016/j.eng.2020.03.007 · 2020 · External reference
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
10.1073/pnas.2021946118 · 2021 · External reference
Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir
2021 · External reference
Role of favipiravir in the treatment of COVID-19
10.1016/j.ijid.2020.10.069 · 2021 · External reference
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
2021 · External reference
10.1021/acs.jcim.0c00613
10.1021/acs.jcim.0c00613 · External reference
10.1021/acs.jcim.7b00564
10.1021/acs.jcim.7b00564 · External reference
10.1021/ja512751q
10.1021/ja512751q · External reference
10.1021/acscentsci.1c00039
10.1021/acscentsci.1c00039 · External reference
10.1021/acsmedchemlett.0c00521
10.1021/acsmedchemlett.0c00521 · External reference
10.1021/acscentsci.1c00258
10.1021/acscentsci.1c00258 · External reference
10.1016/j.phrs.2020.104859
10.1016/j.phrs.2020.104859 · External reference
Underlying mechanisms and candidate drugs for COVID-19 based on the connectivity map database
10.3389/fgene.2020.558557 · 2020 · External reference
10.1021/acs.jmedchem.9b01828
10.1021/acs.jmedchem.9b01828 · External reference
10.1016/j.molliq.2020.114999
10.1016/j.molliq.2020.114999 · External reference
Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations
2021 · External reference
10.1021/acs.jmedchem.9b00640
10.1021/acs.jmedchem.9b00640 · External reference
Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors
2021 · External reference
10.1021/jm301580n
10.1021/jm301580n · External reference
10.1021/acs.jmedchem.0c01063
10.1021/acs.jmedchem.0c01063 · External reference
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19
10.1128/jvi.01819-20 · 2021 · External reference
10.1016/j.str.2020.10.007
10.1016/j.str.2020.10.007 · External reference
10.1039/d0md00367k
10.1039/d0md00367k · External reference
10.1021/acs.jcim.0c01457
10.1021/acs.jcim.0c01457 · External reference
10.3390/v13020173
10.3390/v13020173 · External reference
Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
10.1016/j.antiviral.2021.105020 · 2021 · External reference
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
10.1126/science.abf7945 · 2021 · External reference
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
10.1038/s41594-020-0440-6 · 2020 · External reference
10.1021/acs.jpclett.0c01894
10.1021/acs.jpclett.0c01894 · External reference
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
10.1038/s41467-021-23313-7 · 2021 · External reference
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
10.1038/s41598-021-83229-6 · 2021 · External reference
10.1038/s41467-020-18096-2
10.1038/s41467-020-18096-2 · External reference
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
10.1038/s41598-021-89013-w · 2021 · External reference
10.1016/j.apsb.2020.08.014
10.1016/j.apsb.2020.08.014 · External reference
10.1038/s41467-020-20718-8
10.1038/s41467-020-20718-8 · External reference
Structure-based screening to discover new inhibitors for papain-like proteinase of SARS-CoV-2: An in silico study
10.1021/acs.jproteome.0c00836 · 2021 · External reference
10.1021/acsmedchemlett.0c00684
10.1021/acsmedchemlett.0c00684 · External reference
10.1126/science.abg5827
10.1126/science.abg5827 · External reference
In silico characterization of masitinib interaction with SARS-CoV-2 main protease
10.1002/cmdc.202100375 · 2021 · External reference
10.1126/science.abf1611
10.1126/science.abf1611 · External reference
10.3390/v13020174
10.3390/v13020174 · External reference
10.1002/cmdc.202000924
10.1002/cmdc.202000924 · External reference
10.1039/d0sc06195f
10.1039/d0sc06195f · External reference
10.1021/acs.jmedchem.0c01063
10.1021/acs.jmedchem.0c01063 · External reference
10.1038/s41594-021-00570-0
10.1038/s41594-021-00570-0 · External reference
Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle
10.1128/aac.00900-20 · 2020 · External reference
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
10.1038/s41467-021-20900-6 · 2021 · External reference
10.1021/acscatal.0c05522
10.1021/acscatal.0c05522 · External reference
Peptidomimetic α-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability
2021 · External reference
10.1038/s41467-020-19808-4
10.1038/s41467-020-19808-4 · External reference
10.1038/s41467-021-21118-2
10.1038/s41467-021-21118-2 · External reference
10.1016/j.csbj.2020.07.017 · Admitted local publication
10.1016/j.csbj.2020.11.002 · Admitted local publication
10.1016/j.csbj.2021.06.005 · Admitted local publication
